Nalge Nunc to Market BioCrystal's OptiCell

By HospiMedica staff writers
Posted on 21 Aug 2006
Nalge Nunc International Corporation (Rochester, NY, USA) has entered into a partnership with BioCrystal, Ltd. (Westerville, OH, USA) and acquired global distribution rights of OptiCell and related new products. OptiCell was developed by BioCrystal for cell cultures. The product will be sold and supported globally through the Nalge Nunc international distribution network under the brand name Nunc OptiCell.

The OptiCell device consists of gas-permeable polymer membranes that provide a cell culture growth surface area enclosed within a sealed environment. It accommodates adherent or non-adherent cells and enables visual access to living cells using standard imaging equipment. OptiCell's culture chamber enables cell growth on two parallel, gas-permeable membranes with only 10 ml of cell culture media or reagents.

A rack of 20 OptiCells provides growth surface equivalent to 27 T-75 (75 cm2) culture flasks, in one-fifth the incubation space. Self-sealing access ports greatly reduce risk of contamination, and the clear crystal polystyrene membrane allows high quality imaging of cells. Membranes can be sectioned, making OptiCell useful for cytostaining, transfection, and single cell cloning. The device is ideal for continuous monoclonal antibody production.

Nalge Nunc International is engaged in the design, development, and manufacture of plastic products for use in labware, packaging, biotechnology, and life science applications. "We are pleased to have joined with BioCrystal in bringing this exciting technology to the biomedical research community,” said Steve Silverman, vice president, marketing and product development, Nalge Nunc. "OptiCell further expands the available technologies we provide for in vitro cell culture,” he added.



Related Links:
Nalge Nunc
BioCrystal

Latest Business News